Prefilled Auto Injectors Market

Prefilled Auto Injectors Market Outlook (2023 to 2033)

Expanding at a high-value CAGR of 15%, the global prefilled auto injectors market is extrapolated to attain a valuation of US$ 17 billion by 2033-end, up from its current size of US$ 4.2 billion.

Increasing focus on health and growing demand for self-administration of drugs are expected to be prime factors driving the sales of prefilled auto injectors in the future. High incidence of diabetes across the world is also projected to bolster shipments of prefilled insulin pens and prefilled insulin auto injectors across the forecast period (2023 to 2033).

Rising prevalence of several allergic reactions and high demand for injectable allergy medications are also anticipated to positively impact market development going forward. Prefilled injectable epinephrine pens and adrenaline auto injectors are anticipated to witness a hike in sales owing to the high ubiquity of allergic conditions such as anaphylaxis on a global level.

Favourable reimbursement infrastructure, high healthcare expenditure, rising demand for convenient drug delivery devices, increasing investments in healthcare R&D, and the growing availability of innovative and advanced drug delivery technologies are other prospects that are slated to uplift market potential through 2033. Contrastingly, high costs of prefilled auto injectors and strict regulatory laws are anticipated to have an impeding effect on prefilled auto injector sales throughout the forecast period.

A comprehensive assessment of current and forecasted market scenarios detailing factors such as pricing trends, product standards, local supply, safety regulations, global demand, and other key factors has been discussed extensively in this latest prefilled auto injectors industry research survey by Fact.MR, a market research and competitive intelligence provider.

Report Attributes	Details
Prefilled Auto Injectors Market Size (2023)	US$ 4.2 Billion
Projected Market Value (2033F)	US$ 17 Billion
Global Market Growth Rate (2023 to 2033)	15% CAGR
Asia Pacific Market Growth Rate (2023 to 2033)	15.8% CAGR
United States Market Share in North America (2022)	~85%
Key Companies Profiled	Antares Pharma Inc. Eli Lilly Company Terumo Becton Dickinson and Company Medtronic Pfizer Inc. Gerresheimer Mylan N.V. Amgen Inc.

How are Start-ups changing the Route of Drug Delivery?

“New Companies Focusing on Creating Novel Drug Delivery Devices to Improve Healthcare”

Prefilled auto injector start-ups are focusing on acquiring new capital to advance their research and development of novel technologies and fast-track the launch of these innovative products. The new prefilled auto injector manufacturers are also using their funds to develop creative marketing and business strategies that allow them to compete with the established market players.

• In June 2022, Elektrofi, a biotechnology start-up focusing on the development of monoclonal antibodies and therapeutic proteins that could enable the delivery of biologics through auto injectors and prefilled syringes announced that it had raised US$ 40 billion. The new capital was intended to be used to create a GMP manufacturing line and push its drug delivery technology in clinics.

A more detailed account of the current and forecasted start-up scenario along with new developments has been listed in this updated prefilled auto injectors market research report by Fact.MR.

Which Factors May Restrain Prefilled Auto Injectors Market Evolution?

“High Cost of Auto Injectors and Lengthy Approval Process”

The research and development process of auto injectors is a complex one and involves the use of advanced technologies, which drives up the cost of manufacturing as well and results in costly end products. These high costs limit the sales of prefilled auto injectors in developing and underdeveloped economies that have restricted spending potential. Moreover, the lengthy and stringent regulatory mandates also elongate the pre-approval process for several products and result in expensive prefilled auto injectors.

Frequent product recalls by regulatory bodies are also anticipated to have a hindering effect on the overall market growth in the future. The widespread adoption of pre-filled syringes over auto injectors is also predicted to hurt prefilled auto injector sales going forward.

Country-wise Insights

Why is Japan an Investment-worthy Market for Prefilled Auto Injector Vendors?

“Increasing Incidence of Rheumatoid Arthritis among Elderly”

Japan has a high geriatric population that accounts for nearly 1/3 of its total population and this sect is influentially governing healthcare industry trends in the country. Elderly people are more at risk of having joint and bone-related health issues such as Rheumatoid Arthritis and this is a prime factor that is anticipated to boost prefilled auto injector demand in the country over the coming years.

The growing availability of advanced drug delivery technologies, increasing spending on healthcare, supportive government initiatives, and rising disposable income are other factors that could potentially impact market evolution in Japan throughout the forecast period.

• In June 2022, Otsuka Pharmaceutical Co. Ltd., a leading pharmaceutical company in Japan announced that it had received regulatory approval for an auto injector dosage form for AJOVY® Subcutaneous Injection 225 mg. The AJOVY formulation is used as a preventive treatment for migraine in adults, which is developed by Teva Pharmaceuticals and exclusively developed and distributed by Otsuka in Japan.

Which European Countries Should Prefilled Auto Injector Manufacturers Focus On?

“Germany & United Kingdom to Offer Attractive Business Scope”

Focus on healthcare infrastructure development has increased substantially in the European region in recent years owing to the growing prevalence of chronic diseases and increasing awareness regarding preventive healthcare. Germany and the United Kingdom are anticipated to spearhead prefilled auto injector sales in Europe across the forecast period owing to the increasing availability of novel drug delivery devices and high healthcare expenditure.

• In November 2022, Arecor Therapeutics plc’s subsidiary Tetris Pharma Ltd. announced the launch of a glucagon-prefilled auto injector pen called Ogluo® in Germany. The product is used for the treatment of severe hypoglycaemia in adults and children suffering from diabetes.

Increasing focus on reducing needlestick injuries, growing awareness regarding the benefits of prefilled syringes and auto injectors, and high investments in the development of innovative drug delivery technologies are other aspects that shape prefilled auto injector demand outlook in the aforementioned European countries. Rising approvals for new products and changing regulatory frameworks are also expected to have a positive impact on market growth in this region through 2033.

How Will Sales of Prefilled Auto Injectors Fare in the United States?

“Rapid Adoption of Novel Healthcare Technologies in the Country”

Demand for prefilled auto injectors in the United States accounted for more than 85% of the market share in the North American region in 2022 and the country is estimated to maintain a similar dominant stance across the forecast period. A high incidence of diabetes and anaphylaxis is a prime prospect that is projected to uplift prefilled auto injector sales in the country over the coming years.

• As per the statistics listed on the Centers for Disease Control and Prevention website, around 37.3 billion suffered from diabetes in 2022 in the United States, which accounted for around 11.3% of the total population of the country.

High healthcare spending, rapid adoption of novel drug delivery systems, the presence of key prefilled auto injector suppliers, and rising investments in healthcare research and development activities are other aspects that could potentially boost market growth in the future. The presence of favorable reimbursement and insurance policies in the country is also anticipated to promote shipments of prefilled auto injectors over the next ten years.

Category-wise Insights

Which Indication Accounts for High Prefilled Auto Injector Sales?

“Anaphylaxis Accounts for Dominant Market Share”

Based on indication, the market for prefilled auto injectors is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others.

Epinephrine injection is extensively used in the treatment of several allergic reactions including anaphylaxis, which is a potentially deadly allergic reaction. Increasing incidence of anaphylaxis across the world is projected to primarily boost demand for epinephrine for its treatment and since it is mostly delivered in the form of pre-filled syringes and auto injectors, it is projected to boost market potential over the coming years.

Auto injectors are preferred for several allergy medications since they can be administered by anyone even without any medical training or background. Growing demand for injectable epinephrine to treat several allergic reactions such as anaphylaxis is anticipated to uplift sales of prefilled auto injectors through 2033.

Competitive Landscape :

Leading prefilled auto injector companies are focusing on developing and launching innovative products that help them in bolstering their market stance and boost sales potential.

• In May 2022, Jabil Healthcare, a healthcare division of Jabil Inc. announced the launch of a new auto injector platform that is modular and more affordable than other market alternatives. The product was launched to support sustainable drug delivery in the pharmaceutical industry landscape.
• In October 2021, Ypsomed a leading medical device manufacturer announced the launch of the world’s first auto injector for prefilled syringes with integrated connectivity. The YpsoMate On utilized the proven expertise of the company’s auto injector and opened up new options for digital therapy support as well.
• In April 2020, Teva Pharmaceuticals USA Inc., a leading pharmaceutical manufacturer announced the launch of an auto injector device for AJOVY® (fremanezumab-vfrm) injection in the United States. The drug was used as a preventive treatment for migraine in adults.

Key Segments of Prefilled Auto Injectors Industry Research

• By Indication :

  • Anaphylaxis
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA